Quarterly Sales Analysis of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)
- Author: Zachary Reyes Jun 21, 2017,
Jun 21, 2017, 13:02
On 06/19/2017 close, Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) plummeted -1.92% to $5.10. The company has its outstanding shares of 303.50 million. "The FDA indicated that it considered the resubmission to be a complete response to the CRL.", the firm's analyst wrote.
After a recent check, Adamis Pharmaceuticals Corp (NASDAQ:ADMP)'s 14-day RSI is presently at 59.73.
Currently, the market capitalization of Adamis Pharmaceuticals Corporation (ADMP) is 140.57 Million. According to these analysts, the Low Revenue Estimate for Adamis Pharmaceuticals Corporation is 4.7 Million and the High Revenue Estimate is 4.7 Million. Vanguard Group Inc. now owns 771,773 shares of the specialty pharmaceutical company's stock valued at $3,280,000 after buying an additional 87,974 shares during the last quarter. The Lower end of the earnings estimate is $-0.13, while the higher end of the earnings estimate is $-0.13. After keeping Technical check on movement of stock price comparison to its moving averages like 20, 50 and 200 SMA, we detected following trends of BCRX.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another domain, it was stolen and reposted in violation of USA & global trademark & copyright law. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2017/06/19/adamis-pharmaceuticals-corporation-admp-given-buy-rating-at-maxim-group-updated.html.
Institutional investors have recently added to or reduced their stakes in the stock.
Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter. Looking ahead to earnings forecasts, for the running fiscal period, Wall Street analysts have anticipated that the company will report 0.36 earnings per share.
Adamis Pharmaceuticals Corporation (ADMP) reported sales (ttm) of 9.5 Million, whereas, 1 number of analysts estimated the mean sale of 4.7 million.
Price to Earning P/E ratio and Forward P/E stand at 0 and 34.67 respectively. Geode Capital Management LLC now owns 85,464 shares of the specialty pharmaceutical company's stock worth $363,000 after buying an additional 25,770 shares in the last quarter. This Beta value of Adamis Pharmaceuticals Corporation (ADMP) shows that it has historically moved 8% for every 100% move in the benchmark.
During last 5 trades the stock sticks nearly 17.92%. Over the past month the firm's stock is 42.47%, 14.29% for the last quarter, 70.49% for the past six-months and 68.28% for the previous year. On the bright side, the company's share price has been on the rebound, up more than 316.67% since hitting lows of $2.4 on October 27, 2016.
In terms of Buy, Sell or Hold recommendations, Adamis Pharmaceuticl (NASDAQ:ADMP) has analysts' mean recommendation of 2. The Company is engaged in the development of its specialty pharmaceutical products. The Firm is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company.